Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $11.00 price target on ArQule (NASDAQ: ARQL) following positive additional data ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

ArQule (ARQL) Reports Prelim. Results from Phase 1/2 Study of Miransertib (ARQ 092) in Patients with PIK3CA-related Overgrowth Spectrum & Proteus syndromeJune 17, 2019 9:03 AM ArQule (ARQL) surges 35% after ARQ 531 demonstrates substantial anti-tumor activity and favorable safety profile in Phase 1 studyJune 14, 2019 6:26 AM ArQule (ARQL) Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531 at EHA 2019 MeetingsJune 14, 2019 5:58 AM